Skip to content
value.today

Alexar Therapeutics, Inc.

🇺🇸 Malvern, Pennsylvania, USAPharmaceuticalsFounded 2013
Total raised
$19 M
3 rounds on record
Latest round
$4 M
Dec 2018
First round on record
Jan 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Alexar Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2018$4 MNo. 3$2 to $10 million

Alexar Therapeutics, Inc.: Raise no. 3, Dec 2018

Investors in this round

11 investors had bought by the notice of Apr 1, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pfeiffer · Executive Officer, Director
  • Stephen Tullman · Executive Officer, Director
  • Jason Hong · Director
  • Neal Walker · Director
  • Somasundaram Subramaniam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Pfeiffer, Chief Executive Officer. Newest notice filed Apr 1, 2020 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
May 2017$4 MNo. 2$2 to $10 million

Alexar Therapeutics, Inc.: Raise no. 2, May 2017

Investors in this round

26 investors had bought by the notice of Jun 8, 2017: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $3 M still to sell
Smallest investment taken
$2,900
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pfeiffer · Executive Officer, Director
  • Douglas Gessl · Executive Officer
  • Stephen Tullman · Executive Officer, Director
  • Jason Hong · Director
  • Neal Walker · Director
  • Somu Subramaniam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Pfeiffer, Chief Executive Officer. Newest notice filed Jun 8, 2017. Read the notice at the SEC.

equitySEC
Jan 2014$11 MNo. 1$10 to $50 million

Alexar Therapeutics, Inc.: Raise no. 1, Jan 2014

Investors in this round

35 investors had bought by the notice of Apr 28, 2015: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $22 M offered; $11 M still to sell
Smallest investment taken
$12,500
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,900,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pfeiffer · Executive Officer, Director
  • Douglas Gessl · Executive Officer
  • Kamil Ali-Jackson · Executive Officer
  • Raju Mohan · Executive Officer
  • Jason Hong · Director
  • Neal Walker · Director
  • Somu Subramaniam · Director
  • Stephen Tullman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Pfeiffer, Chief Executive Officer. Newest notice filed Apr 28, 2015 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alexar Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).

    SEC Form D · Apr 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Alexar Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alexar Therapeutics, Inc.
NameRoleNamed in
David PfeifferExecutive officerApr 2020
Stephen TullmanExecutive officerApr 2020
Douglas GesslExecutive officerJan 2019
Kamil Ali-JacksonExecutive officerApr 2015
Raju MohanExecutive officerApr 2015
David PfeifferDirectorApr 2020
Jason HongDirectorApr 2020
Neal WalkerDirectorApr 2020
Somasundaram SubramaniamDirectorApr 2020
Stephen TullmanDirectorApr 2020
Somu SubramaniamDirectorJun 2017